Providence Therapeutics Holdings Inc.
https://providencetherapeutics.com/
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Providence Therapeutics Holdings Inc.
Providence’s COVID-19 mRNA Vaccine Challenger Seen In Phase III In Q1
A possible alternative to Pfizer and Moderna’s COVID-19 vaccines, Providence Therapeutics’ mRNA candidate is seen moving into Phase III trials during the calendar first quarter of next year. While partners Everest Medicines and Biological E have kept the ball rolling, the Canadian biotech will seek further funding, CEO Brad Sorenson tells Scrip in this audio interview.
Chinese Biotechs' Foray Into mRNA Enters New Chapter With $100m Everest Deal
Everest Medicines’ deal with Canadian biotech Providence Therapeutics contains a full transfer of technology which may be appealing to Chinese regulators.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Antisense, Oligonucleotides